Mycobacterium Abscessus Infection Clinical Trial
Official title:
A Prospective, Open Labeled, Multi-Center, Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With NTM (Specifically MABSC)
A Prospective, Open labeled, multi-Center, Evaluation of the Efficacy Safety and Tolerability
of Nitric Oxide Given Intermittently via Inhalation to Subjects with NTM (specifically MABSC)
Nitric Oxide (NO) has been shown to play a critical role in various biological functions. In
the airways, NO is considered to play a key role in the innate immune system in which the
first-line of host defense against microbes is built.
In vitro studies suggested that NO, in part per million (ppm) concentrations, possesses
anti-microbial activity against a wide variety of phyla including fungi, and
antibiotic-resistance bacteria.
In this study the investigators wish to evaluate the efficacy, safety and tolerability of 160
ppm Nitric Oxide intermittently delivered via inhalation to subjects infected with
Non-tuberculosis mycobacteria (NTM), specifically with MABSC.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04922554 -
Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)
|
Phase 2 | |
| Completed |
NCT05354583 -
Treatment Outcome Between Mycobacterium Abscessus Infection in Chronic Lung Disease and Acquired Interferon-gamma Autoantibody Syndrome
|
||
| Active, not recruiting |
NCT06004037 -
Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex
|
Phase 2 | |
| Completed |
NCT04685720 -
A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients
|
N/A |